Safety and Efficacy of Osimertinib in Treating an EGFR-Mutant Lung Cancer Patient with a Germline EGFR T790M Mutation

被引：0

作者：

Ma, W. ^{[1
]}

Gong, J. ^{[1
]}

Shan, J. ^{[2
]}

Lewis, D. ^{[2
]}

Xiao, W. ^{[3
]}

Hung, J. ^{[4
]}

Moore, E. H. ^{[5
]}

Zhang, Y. ^{[6
]}

Mans, N. Z. ^{[7
]}

Welborn, J. ^{[5
]}

Lam, K. S. ^{[3
]}

Li, T. ^{[1
]}

机构：

[1] Univ Calif Davis, Ctr Comprehens Canc, Div Hematol & Oncol, Sacramento, CA 95817 USA

[2] Albert Einstein Coll Med, Dept Genet, New York, NY USA

[3] Univ Calif Davis, Dept Biochem & Mol Med, Sacramento, CA 95817 USA

[4] Sierra Nevada Med Grp, Grass Valley, CA USA

[5] Univ Calif Davis, Sch Med, Sacramento, CA 95817 USA

[6] Univ Calif Davis, Sch Med, Dept Pathol & Lab Med, Sacramento, CA 95817 USA

[7] Univ Calif Davis, Hereditary Canc Program, Ctr Comprehens Canc, Sacramento, CA 95817 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期

关键词：

osimertinib; lung cancer; Germline EGFR T790M;

D O I：

10.1016/j.jtho.2017.09.590

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA 15.08

引用

页码：S1863 / S1864

页数：2

共 50 条

[21] The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma
Zhang, Qiuyi
Ke, Ee
Niu, Feiyu
Deng, Wei
Chen, Zhihong
Xu, Chongrui
Zhang, Xuchao
Zhao, Ning
Su, Jian
Yang, Jinji
Yan, Honghong
Wu, Yilong
Zhou, Qing
ONCOTARGET, 2017, 8 (03) : 4994 - 5002
[22] Role of T790M Mutation in EGFR-TKI Rechallenge for Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer
Zhang, Qiu-Yi
Ke, E-E
Deng, Wei
Niu, Fei-Yu
Zhao, Ning
Su, Jian
Chen, Zhi-Hong
Yang, Jin-Ji
Xu, Chong-Rui
Yan, Hong-Hong
Wu, Yi-Long
Zhou, Qing
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S271 - S271
[23] Usefulness of Nanofluidic Digital PCR Arrays to Quantify T790M Mutation in EGFR-mutant Lung Adenocarcinoma
Isobe, Kazutoshi
Hata, Yoshinobu
Tochigi, Naobumi
Kaburaki, Kyohei
Kobayashi, Hiroshi
Makino, Takashi
Otsuka, Hajime
Ishida, Fumiaki
Hirota, Nao
Sano, Go
Sugino, Keishi
Sakamoto, Susumu
Takai, Yujiro
Shibuya, Kazutoshi
Iyoda, Akira
Homma, Sakae
CANCER GENOMICS & PROTEOMICS, 2015, 12 (01) : 31 - 37
[24] Activation of IGF1R confers acquired resistance to osimertinib in EGFR-mutant NSCLC with T790M mutation
Hayakawa, Daisuke
Takahashi, Fumiyuki
Tajima, Ken
Mitsuishi, Yoichiro
Nakamura, Ikuko
Winardi, Wira
Shirai, Yukina
Miyashita, Yosuke
Yamada, Tomoko
Miura, Keita
Torasawa, Masahiro
Matsuda, Hironari
Asao, Tetsuhiko
Shukuya, Takehito
Takahashi, Kazuhisa
CANCER SCIENCE, 2022, 113 : 1060 - 1060
[25] Quantification of T790M mutation in EGFR-mutant lung adenocarcinoma with nanofluidic digital PCR arrays.
Isobe, Kazutoshi
Hata, Yoshinobu
Tochigi, Naobumi
Kaburaki, Kyohei
Makino, Takashi
Otsuka, Hahjime
Sato, Keita
Sano, Go
Sugino, Keishi
Sakamoto, Susumu
Takai, Yujiro
Iyoda, Akira
Homma, Sakae
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[26] Osimertinib or platinum-pemetrexed in EGFR T790M positive lung cancer
Bernard-Tessier, A.
ONCOLOGIE, 2017, 19 (5-6) : 203 - 204
[27] Predictive factors and prognostic significance of T790M mutation in patients with EGFR-mutant NSCLC
Hwang, Ji An
Choi, Chang-Min
Lee, Jae Cheol
EUROPEAN RESPIRATORY JOURNAL, 2017, 50
[28] Osimertinib for EGFR-Mutant NSCLC Patients With Acquired T790M and EGFR Amplification After First-Generation EGFR-TKI Resistance
Zhang, Yidan
Xu, Yingqi
Xu, Jianlin
Zhong, Hua
Xia, Jinjing
Zhong, Runbo
CANCER SCIENCE, 2024,
[29] Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer
Soejima, Kenzo
Yasuda, Hiroyuki
Hirano, Toshiyuki
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (01) : 31 - 38
[30] Does T790M Disappear? Successful Gefitinib Rechallenge After T790M Disappearance in a Patient With EGFR-Mutant Non-Small-Cell Lung Cancer
Hata, Akito
Katakami, Nobuyuki
Kaji, Reiko
Fujita, Shiro
Imai, Yukihiro
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (03) : E27 - E29

← 1 2 3 4 5 →